<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02555059</url>
  </required_header>
  <id_info>
    <org_study_id>18235</org_study_id>
    <nct_id>NCT02555059</nct_id>
  </id_info>
  <brief_title>Special Drug Use Investigation of Ciproxan Injection in Pediatrics</brief_title>
  <official_title>Special Drug Use Investigation of CiproxanÂ® Injection in Pediatrics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective in this study is collecting post-marketing information on the safety and
      efficacy of Ciproxan injection under the routine clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This company-sponsored study is an one-arm, prospective, and, cohort-observational study in
      pediatrics (less than 15 years old) administered Ciproxan injection. All patients in the
      contracted institute should be enrolled into this study. Consequently 45 cases will be is
      planned to be enrolled in three-year period Target population is pediatrics with a diagnosis
      of complicated cystitis, pyelonephritis, cystic fibrosis, or anthrax infected by
      ciprofloxacin-active microorganisms, i.e. Bacillus anthracis, Escherichia coli, Pseudomonas
      aeruginosa. The treatment should be performed based on the product label in Japan. The
      standard observation will be performed until the last date of the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of musculoskeletal adverse events.</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Existence of Bacillus anthracis or Escherichia coli or Pseudomonas aeruginosa in urine(Y/N)</measure>
    <time_frame>At week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as measure of safety and tolerability</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Rated by physician with 3-grade scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events based on abnormal laboratory measurements</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax</condition>
  <arm_group>
    <arm_group_label>BAYQ3939</arm_group_label>
    <description>Pediatrics patients treated with Ciproxan injection in daily clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cipro (Ciprofloxacin, BAYQ3939)</intervention_name>
    <description>Treatment parameters following the physician's decision based on the summary of product characteristics.</description>
    <arm_group_label>BAYQ3939</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Female and male pediatric patients (less than 15 years old) with a diagnosis of complicated
        cystitis, pyelonephritis, cystic fibrosis, or anthrax infected by ciprofloxacin-active
        microorganisms, i.e. Bacillus anthracis, Escherichia coli, Pseudomonas aeruginosa, are
        enrolled after the decision for treatment with Ciproxan injection has been made by the
        investigator.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male pediatric patients (less than 15 years old) with a diagnosis of
             complicated cystitis, pyelonephritis, cystic fibrosis, or anthrax infected by
             ciprofloxacin-active microorganisms, i.e. Bacillus anthracis, Escherichia coli,
             Pseudomonas aeruginosa.

          -  Patients for whom the decision to initiate treatment with Ciproxan injection was made
             as per investigator's routine treatment practice.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>(+) 1-888-8422937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2015</study_first_submitted>
  <study_first_submitted_qc>September 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2015</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ciprofloxacin</keyword>
  <keyword>Japan</keyword>
  <keyword>Post-marketing surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Pyelonephritis</mesh_term>
    <mesh_term>Anthrax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

